Rexahn Pharmaceuticals, Inc. Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117
5/30/2012 10:11:53 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry [55: 4521-4525, 2012] on the anti-tumor activity of its RX-3117 compound.
comments powered by